CA1142090A - Topical anti-inflammatory composition - Google Patents
Topical anti-inflammatory compositionInfo
- Publication number
- CA1142090A CA1142090A CA000344269A CA344269A CA1142090A CA 1142090 A CA1142090 A CA 1142090A CA 000344269 A CA000344269 A CA 000344269A CA 344269 A CA344269 A CA 344269A CA 1142090 A CA1142090 A CA 1142090A
- Authority
- CA
- Canada
- Prior art keywords
- composition
- weight
- phenyl salicylate
- composition according
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Abstract Topical Anti-Inflammatory Composition A composition for treating inflammation in humans comprises from 0.1% to 10% by weight of phenyl salicylate in a carrier of a lower alkanol and propylene glycol and/
or benzyl alcohol.
The composition may additionally contain from 0.1% to 2% by weight of eugenol for the treatment of UV-induced erythema.
or benzyl alcohol.
The composition may additionally contain from 0.1% to 2% by weight of eugenol for the treatment of UV-induced erythema.
Description
- L -Title: Topical Anti-lnflamrnatory Composi-tion This invention relates to the field of anti-inflarnmatory compositions, and in particular to such compositlons containing phenyl salicylate.
Phenyl salicyla-te is known in the art as an analgesic, antipyretic and antirheumatic. I-t is also known as an intestinal antiseptic for the trea-tment of diarrhea and as an external disinfectant. In addition, phenyl salicylate has been used as an enteric coating for tablets.
- The present invention is based on the surprising discovery that phenyl salicylate is useful as a topical anti-inflc~mmatory when combined with a suitable pharmaceutically acceptable carrier into a topical composition and applied to the inflammed skin of a human or animal .
The composition preferably includes eugenol, which is known in the art as a dental analgesic. The preferred concentration of phenyl salicylate in the topical composition of the invention is from 0.1% to 10.0% by weight.
The preferred pharrnaceutically acceptable carrier with 20 ~ which phen~l salicylate is combined comprises a lower alkanol, and ethyl alcohol is especially preferred.
Other suitable carriers comprise benzyl alcohol or propylene glycol.
The carrier may comprise a mixture of one or more lower alkanols in combination with propylene glycol, or in combination with propylene glycol and benzyl alcohol.
Accordiny to a particularly preferred embodiment of the present invention, the concentration of phenyl salicylate is from 0.1~ to 2~5% by weight, more preferably about l~ by weight.
Although phenyl salicyla-te may be the sole active ingredient in the topical co~p'osition, an enhancement of the anti-inflammatory activity occurs when eugenol is incorporated into the composition. Non-toxic solvents,~ _.
,~
o surfactants" emollien-ts, etc., which are compatible with phenyl salicylate may also be included in the composition.
In ad~ition, topical anesthe-tics and analgesics may be included in -the composition.
It has also been discovered that the use of phenyl salicylate for the treatmen~ of W-induced erythema is `. enhanced by -the addition of eugenol, and in a preferred embodiment of the invention for use i.n this treatment, the amount of phenyl salicylate is from 1.0% to 10.0% by weight and the amount of eugenol is from 0.1% to 2.0% by weight. The carriers may be any of the above referred to carriers and the resultan-t pharmaceutical composition is as describedabove in topical application form so that it may be applied to the skin of a hurnan or animal suffering from inf].amma-tion.
It has been found to be advantageous to include in the compositions of the present invention a penetrating agent such as methyl salicylate. The presence of such an agent in an amount of 1% to 10% by weight, preferably 2% to 5~ by weight and particularly about 3% by weight, substantially enhances the ability of the present compositions to penetrate the skin, thereby enhancing effectiveness.
The concentration of phenyl salicylate is not critical and will depend, as one skilled in the art will appreciate, upon a variety of factors including, location, type and severity of the disorder being treated.
The amount applied to~ically will vary, depending upon a number of considerations. In this regard, the art further appreciates that in many instances a relatively strong concentration or more frequent application of a weaker concentration may be equally effec-tive. The objective is to obtain the maximurn therapeutic response with minim~n dosage.
The following non-limitative examples more particularly illustrate the present invent~on:
Phenyl salicyla-te is known in the art as an analgesic, antipyretic and antirheumatic. I-t is also known as an intestinal antiseptic for the trea-tment of diarrhea and as an external disinfectant. In addition, phenyl salicylate has been used as an enteric coating for tablets.
- The present invention is based on the surprising discovery that phenyl salicylate is useful as a topical anti-inflc~mmatory when combined with a suitable pharmaceutically acceptable carrier into a topical composition and applied to the inflammed skin of a human or animal .
The composition preferably includes eugenol, which is known in the art as a dental analgesic. The preferred concentration of phenyl salicylate in the topical composition of the invention is from 0.1% to 10.0% by weight.
The preferred pharrnaceutically acceptable carrier with 20 ~ which phen~l salicylate is combined comprises a lower alkanol, and ethyl alcohol is especially preferred.
Other suitable carriers comprise benzyl alcohol or propylene glycol.
The carrier may comprise a mixture of one or more lower alkanols in combination with propylene glycol, or in combination with propylene glycol and benzyl alcohol.
Accordiny to a particularly preferred embodiment of the present invention, the concentration of phenyl salicylate is from 0.1~ to 2~5% by weight, more preferably about l~ by weight.
Although phenyl salicyla-te may be the sole active ingredient in the topical co~p'osition, an enhancement of the anti-inflammatory activity occurs when eugenol is incorporated into the composition. Non-toxic solvents,~ _.
,~
o surfactants" emollien-ts, etc., which are compatible with phenyl salicylate may also be included in the composition.
In ad~ition, topical anesthe-tics and analgesics may be included in -the composition.
It has also been discovered that the use of phenyl salicylate for the treatmen~ of W-induced erythema is `. enhanced by -the addition of eugenol, and in a preferred embodiment of the invention for use i.n this treatment, the amount of phenyl salicylate is from 1.0% to 10.0% by weight and the amount of eugenol is from 0.1% to 2.0% by weight. The carriers may be any of the above referred to carriers and the resultan-t pharmaceutical composition is as describedabove in topical application form so that it may be applied to the skin of a hurnan or animal suffering from inf].amma-tion.
It has been found to be advantageous to include in the compositions of the present invention a penetrating agent such as methyl salicylate. The presence of such an agent in an amount of 1% to 10% by weight, preferably 2% to 5~ by weight and particularly about 3% by weight, substantially enhances the ability of the present compositions to penetrate the skin, thereby enhancing effectiveness.
The concentration of phenyl salicylate is not critical and will depend, as one skilled in the art will appreciate, upon a variety of factors including, location, type and severity of the disorder being treated.
The amount applied to~ically will vary, depending upon a number of considerations. In this regard, the art further appreciates that in many instances a relatively strong concentration or more frequent application of a weaker concentration may be equally effec-tive. The objective is to obtain the maximurn therapeutic response with minim~n dosage.
The following non-limitative examples more particularly illustrate the present invent~on:
2~
, - 3 ., Example l A topical composition was prepared by combining the following ingredients.
.' 5% Phenyl Salicylate and 0.25% eugenol in a vehicle consisting of:
, - 3 ., Example l A topical composition was prepared by combining the following ingredients.
.' 5% Phenyl Salicylate and 0.25% eugenol in a vehicle consisting of:
3% rllethyl Salicylate ~` 12% Propylene Glycol 85% Absolute Ethyl Alcohol.
.
Example 2 A topical composition was prepared by combining the following ingredients.
~` 2.5% Phenyl Salicylate and 0.5% eugenol in a vehicle consisting of:
20% Propylene Glycol 80% Absolute Ethyl Alcohol.
.
Example 3 ~: A topical composition was prepared by combining the following ingredients.
` 1% Phenyl Salicylate and 1% eugenol in a vehicle consisting of:
` 20 3% Methyl Salicylate 5% Benzyl Alcohol 12% Propylene Glycol 40% Isopropyl Alcohol 40% Absolute Ethyl Alcohol.
- A topical composition was prepared by combining the following ingredients.
r 10% Phenyl Salicylate and 0.1% eugenol in a vehicle .
consisting of:
0.25% Oil of Allspice 0.25~ Oil of Bay 3.0~ Methyl Salicylate 5.0% Benzyl Alcohol 15.0~ Propylene Glycol 76.5% Absolute Ethyl Alcohol.
x mple 5 A topical composition was prepared by combininy the lOfollowing inyredients.
5% Phenyl Salicyla-te in a vehicle consi.sting of:
3% Methyl Salicylate 12% Propylene Glycol 85% Absolute Ethyl Alcohol.
.
Example 2 A topical composition was prepared by combining the following ingredients.
~` 2.5% Phenyl Salicylate and 0.5% eugenol in a vehicle consisting of:
20% Propylene Glycol 80% Absolute Ethyl Alcohol.
.
Example 3 ~: A topical composition was prepared by combining the following ingredients.
` 1% Phenyl Salicylate and 1% eugenol in a vehicle consisting of:
` 20 3% Methyl Salicylate 5% Benzyl Alcohol 12% Propylene Glycol 40% Isopropyl Alcohol 40% Absolute Ethyl Alcohol.
- A topical composition was prepared by combining the following ingredients.
r 10% Phenyl Salicylate and 0.1% eugenol in a vehicle .
consisting of:
0.25% Oil of Allspice 0.25~ Oil of Bay 3.0~ Methyl Salicylate 5.0% Benzyl Alcohol 15.0~ Propylene Glycol 76.5% Absolute Ethyl Alcohol.
x mple 5 A topical composition was prepared by combininy the lOfollowing inyredients.
5% Phenyl Salicyla-te in a vehicle consi.sting of:
3% Methyl Salicylate 12% Propylene Glycol 85% Absolute Ethyl Alcohol.
Claims (8)
PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A pharmaceutical composition in topical application form useful for treating inflammation in humans and animals, characterized in that it comprises from 0.1 to 10% of phenyl salicylate by weight of the composition in combination with a pharmaceutically acceptable carrier suitable for topical application to the skin of a human or animal.
2. A composition according to claim 1, characterized in that it further comprises a therapeutically active amount of eugenol.
3. A composition according to claim 2, characterized in that the concentration of eugenol is from 0.1% to 2% by weight of the composition.
4. A composition according to claim 1, characterized in that the carrier comprises a lower alkanol, propylene glycol, or benzyl alcohol, or a mixture of any thereof.
5. A composition according to claim 4, characterized in that the lower alkanol is ethanol.
6. A composition according to claim 1, characterized in that the concentration of phenyl salicylate is from 0.1% to 2.5% by weight of the composition.
7. A composition according to claim 6, characterized in that the concentration of phenyl salicylate is 1% by weight of the composition.
8. A composition according to claim 6, characterized in that the concentration of phenyl salicylate is 2.5% by weight of the composition and the concentration of eugenol is 0. 25% by weight.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US596379A | 1979-01-24 | 1979-01-24 | |
| US005,963 | 1979-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1142090A true CA1142090A (en) | 1983-03-01 |
Family
ID=21718593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000344269A Expired CA1142090A (en) | 1979-01-24 | 1980-01-23 | Topical anti-inflammatory composition |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1142090A (en) |
-
1980
- 1980-01-23 CA CA000344269A patent/CA1142090A/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU66600A (en) | Pharmaceutical compositions capable of being gelled | |
| IL111647A (en) | Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation | |
| JPS63500171A (en) | Pharmaceutical vehicles for reducing transdermal flow | |
| IE940583L (en) | Topical antimicrobial pharmaceutical compositions | |
| CA2406024A1 (en) | Methods for improving size and appearance of a wound | |
| KR880000091A (en) | Topical Pharmaceutical Compositions Method of Preparation and Use thereof | |
| EP0382066A3 (en) | Use of dihydroliponic acid as an analgetic, antiphlogistic and/or cytoprotective agent | |
| IE791806L (en) | Gastroprotective mollusc extract | |
| EP0932338A4 (en) | Pesticidal composition and method of use | |
| US4404198A (en) | Phenyl Salicylate as a topical anti-inflammatory | |
| CA2284774A1 (en) | Theobromine antitussive compositions | |
| PL311637A1 (en) | Poured over preparations containing a polymer as well as glycerides and glycols | |
| WO1999043636A3 (en) | Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs | |
| EP0218410A2 (en) | Use of 1-hydroxy-2-pyridones in the treatment of acne | |
| GEP19991872B (en) | Novel Taxoids, Preparations Thereof, and Pharmaceutical Compositions Containing Same | |
| CA1142090A (en) | Topical anti-inflammatory composition | |
| JPH07557B2 (en) | Composition for treating dermatitis | |
| TR200103144T2 (en) | New compounds | |
| GEP20043231B (en) | Resorcinol Composition | |
| RU98101105A (en) | NEW APPLICATION FOR MEDICAL PURPOSES | |
| DE60032246D1 (en) | COMPOSITIONS CONTAINING TETRACYCLINE FOR THE TREATMENT OR PREVENTION OF MUCOSITIS | |
| CA2001568A1 (en) | Medicament for treating toxoplasmosis | |
| RU99118510A (en) | COMPOSITION FOR THE TREATMENT OR PREVENTION OF PROSTATE CANCER | |
| KR910002455A (en) | Pharmaceutical compositions containing acrylic acid derivatives and their use as medicaments | |
| AU4519289A (en) | Medicament for the treatment of cryptosporidiosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |